Dr. Allan is Chairman of the Board at Insmed Incorporated and has served as the President and Chief Executive Officer since the company’s inception in May 2000. Insmed is a research-driven biopharmaceutical company with broad expertise in and innovative approaches to the development of protein-based therapeutics, and efficiently moving product candidates through the regulatory approval process. The Company's goal is to lead the emerging field of follow-on biologics by creating biosimilar versions of existing protein-based therapies as they come off patent. Dr. Allan was President and a Director of Insmed Pharmaceuticals Inc., Insmed Incorporated’s predecessor, from January 1994 to 2000 and has 27 years of experience in pharmaceutical drug development. Prior to joining Insmed, Dr. Allan was Vice President of Drug Development at Whitby Research, Inc., where he was responsible for building and directing a development organization that managed a broad portfolio of drug development candidates. Before his association with Whitby Research, Dr. Allan was the Head of the Cardiovascular Section at Wellcome Research Laboratories. Dr. Allan received his B. Sc. in Pharmacology from the University of Sunderland, and his Ph.D. in Pharmacology from Cornell University Medical College.

Pascal Brenneisen, CEO of Sandoz Portugal - the Generics Division of Novartis - in charge since beginning of 2007. Previous job experiences within Sandoz Generics, Novartis Consumer Health, Sandoz Corporate and Ciba Pharmaceuticals include General Management, Strategic Business Development, Marketing & Sales, Operations, Product Supply Management and Operational Auditing. Assignments in headquarters and in over 30 countries, including long-term international jobs in Shanghai/China, in Istanbul/Turkey, in Munich/Germany and in Paris/France. Graduated from the university of Basel/Switzerland with a masters degree in law.

Heather Bresch is Mylan’s Executive Vice President and Chief Operating Officer, responsible for the Company’s global commercial and technical operations, strategic planning, business development and international affairs. She also oversees the integration of Mylan’s recent acquisition of Merck Generics. Throughout her 16-year career with Mylan, Bresch has held various positions of increasing responsibility. Most recently, she served as Mylan’s Head of North American Operations and Chief Integration Officer. As Head of North American Operations, Heather was responsible for Mylan Pharmaceuticals, Mylan Technologies and UDL Laboratories. In her role as Chief Integration Officer, she managed the successful integration of Matrix Laboratories, in which Mylan took a controlling stake in January of 2007, and has been leading the integration team working with Merck Generics, which Mylan acquired in October 2007. Prior to these positions, she served as Senior Vice President of Strategic Development in the Office of the CEO. In addition to her responsibilities with Mylan, Bresch has served two consecutive terms as Chairman of the Generic Pharmaceutical Association and one term as its Vice Chairman. She has been actively involved in critical industry issues, including the passage of the 2003 Medicare Modernization Act, a Congressional revision to the Hatch-Waxman Act of 1984, which helped ensure consumer access to affordable pharmaceuticals. Bresch received an undergraduate degree from West Virginia University.

Frances graduated from Magdalen, Oxford, in Biochemistry and immediately joined Savory Milln as a UK pharmaceuticals analyst. Following its takeover by Swiss Bank Corporation, she took up a role in pan-European pharmaceuticals coverage at IMI before moving to Nomura in 1994. At Nomura, she initially specialised in central European pharmaceuticals companies before shifting to a broader role covering the European generic drug sector. She produces regular research on the sector, including Generics in Europe, a guide to the European generics industry, and the European Generics Quarterly. She also has a particular focus on the European (and global) emerging markets, having tracked the generics sector in central Europe since the mid 1990s. Frances is a CFA charterholder.

Tony Foreman is the Commercial Director of Alliance Healthcare, part of the international pharmacy-led Health and Beauty group, Alliance Boots. With more than 20 years experience in the pharmaceutical industry, Tony has been the driving force behind some of the most exciting recent innovations in European pharmaceutical wholesaling, not least Almus Pharmaceuticals, of which he is also CEO. Launched just 5 years ago in the UK, the Almus range of generic medicines has won numerous awards, and has been described as the gold standard in patient-safe packaging. It is now present in 4 European markets and enjoys a 20 per cent market share by volume in the UK. Tony is currently working on expanding the reach of Almus, and of Alliance Boots’ patient care range – Alvita. In addition, he oversees global sourcing of generics, surgicals and diagnostic products. Most recently, Tony has established Almus Pharmaceuticals USA, a joint venture company set up in 2007 with Cardinal Health. Serving as a Director on the Board of Almus Pharmaceuticals USA, Tony’s role along with the other board directors is to launch a range of Almus medicines in the US market.

Ezio Frisa has been involved in the Pharma and medical business for almost 25 years He started his carrier in Johnson & Johnson for hospital products covering major responsibilities in the Marketing and Sales areas. After, he moved to the Pharma business with BASF Pharma where he followed a varied career in business development, commercial and general management both national and international. In 1996, he started-up GNR, now Sandoz, the first generics company which entered into the Italian market. From 2001 to 2006 Ezio was Managing Director of Pliva Pharma, where he founded the business in Italy. In 2007 he joined Torrent Pharma to start-up the business in Italy and Portugal.

Dr. Huacheng Wei, holds position of Chairman of the Board at both Beijing Pharmaceutical Group Co., Ltd. and Beijing Double-Crane Pharmaceutical Co.,Ltd. two of leading pharmaceutical manufacturers and Marketers in China, and Chairman of Medical & Pharmaceutical Commercial Association of China Federation of Industry & Commerce. As one of China pharmaceutical industry leaders, Dr. Wei has been dedicated to the study and practice on “Theory of Longevity Enterprise”. In the paper of “Research of the longevity corporation—Corporate Culture and the Living Company” Dr. Wei has presented the model of the long-life corporation including the model of the living corporation. He has published many papers of corporate culture and globalization of China Pharmaceutical Company, etc. Dr. Wei networks also very actively with international pharmaceutical organizations and associations such as the BayHelix Groups, the Sino-American Pharmaceutical Association(SAPA) and so on. He has been invited to many international conferences as speaker. He received his PhD at China Huazhong University of Science & Technology (2005), MBA at Tsinghua University (1999).

Michael Kotsanis serves as president, Europe, Middle East and Africa (EMEA), for Hospira, where he is responsible for developing strategy, delivering growth and attaining market leadership in the EMEA region. Kotsanis joined Hospira following its acquisition of Mayne Pharma, Ltd., and has nearly 20 years of experience in the pharmaceutical industry. At Mayne, he served most recently as president, Asia-Pacific, where he led commercial activities in sales, marketing, regulatory, clinical trials, contract manufacturing and contract fee-for-service product development. In addition, he has had prior responsibility for manufacturing, quality and associated functions within the region. Kotsanis also served as vice president, Commercial Operations, for Australia and New Zealand and vice president, Asia-Pacific, for the company. He joined Mayne from F H Faulding Pharmaceuticals, where he managed two sales divisions and held responsibility for sales and marketing efforts in Australia and New Zealand. Prior to Faulding, Kotsanis held a variety of sales and marketing positions with Boehringer Ingelheim, Ltd. Kotsanis earned a bachelor's degree from Monash University, a graduate diploma in business from Edith Cowan University and a master's degree in business from the University of Technology, all in Australia.

I got my MA in biochemistry and PhD in pharmacology at Charles University, Prague, Czechia. My scientific career covered development of biochemical screening methods and experimental and clinical pharmacokinetics. After joining Zentiva in 1993 I worked as project manager implementing project management system within R&D, head of product strategy responsible for outlining pipeline, director of strategic marketing and director of intellectual property. I founded a patent department in mid of nineties, served as a liaison between R&D and strategic marketing deciding product strategy tailored to Zentiva markets and introduced financial project evaluation as a standard tool for a product decision tree. Since 1995 Zentiva grew from small local company to regional player with three development centres, 6500 employees and turnover above USD 1 billion operating in all Central/Eastern European countries. My main activities currently cover patents, trademarks, contract development, company´s future product pipeline and evaluation of new projects for development. My corporate trademark department handles nearly one thousand trademarks registered throughout Europe and CIS countries. In last 8 years Zentiva applied for more than 200 patent applications, we perform annually hundreds of patent searches and produce tens of patent reports. My colleagues are working closely with R&D staff to find most suitable ways curving around patents. Due to their effort Zentiva had not lost a single patent case and we are able to launch generic products just in time without any withdrawal. Nowadays Zentiva has a viable product pipeline till 2020 securing its future profitable growth.

Dr Fritz Oesterle, who was born on 7 April 1952 in Stuttgart (Baden-Württemberg) where he grew up, took his 'Abitur', qualifying him for university, in 1971. Subsequent to this, he studied Law at the University of Tübingen. In 1976 he completed his first state examinations. From 1977 to 1979 he worked as an academic assistant to Prof Dr Münzberg, who held the Chair in Civil Law at the University of Tübingen. He graduated at the end of 1979 as a ‘Doctor of Law’ and was awarded the Reinhold-und-Maria-Teufel-Stiftung Prize. Between 1979 and 1981 he completed a period of probationary training as a lawyer, which he completed in 1981, passing his second state examinations in Law. In 1981 Fritz Oesterle was admitted as a lawyer and was employed until 1988 as a partner at Gleiss Lutz Hootz Hirsch & Partners, Stuttgart. In 1989 he founded his own legal practice together with Dr Frank Oppenländer. In 1998 Fritz Oesterle attended Harvard Business School. Fritz Oesterle has been Chief Executive Officer and Chairman of the Management Board of Celesio AG since 1 January 1999. From 2001 until mid 2007, Fritz Oesterle was a member of the Steering Committee for GIRP, the European Association of Pharmaceutical Wholesalers and from 2003 to mid 2007, also the Vice President of GIRP. In January 2006, Fritz Oesterle has been appointed as the Honorary British Consul for Baden-Württemberg. On 1 October 2006 Fritz Oesterle was appointed to the Franz Haniel & Cie. GmbH management board where his responsibilities include Haniel's holding in Celesio.

As a qualified lawyer, Julia got her start in intellectual property law and pharmaceuticals with the Australian law firm, Corrs Chambers Westgarth. Prior to joining Corrs in 2000, she worked in project and contract management for in the construction industry. Since joining Mayne Pharma in 2003, Julia has provided ‘cradle to grave’ IP support for a number of successful products, which has allowed her to gain an in-depth understanding of the IP framework for pharmaceuticals around the world, including patent extensions, Hatch-Waxman legislation, PM(NOC) regulations and litigation in a number or jurisdictions. She was one of the authors of the recent European Generic Medicines Association report entitled “Patent-Related Barriers To Market Entry For Generic Medicines In The European Union”, launched in June 2008. After Hospira, Inc. acquired Mayne Pharma in February 2007, Julia took up the role of Intellectual Property Director & Counsel with Hospira, Inc. Julia earned her Master of Laws (Intellectual Property) from the University of Melbourne, and also holds a Bachelor of Laws/Bachelor of Sciences degree.

Dr Vikash Salig serves as Chief Executive Officer for Dr Reddy's Laboratories (Pty) Ltd, South Africa and Executive Director of Venturepharm. He was the founding director and shareholder in Venturepharm Pty Ltd. Venturepharm’s strategy is to tie up with a strong R&D generic pharmaceutical partner/s to leverage the expertise within the group for the South African public and private sectors, and to capitalize on the existing network developed in Africa. Venturepharm has entered into a joint venture with Dr Reddy’s Laboratories (Ltd) to form Dr Reddy’s Laboratories (Pty) Ltd in South Africa. Venturepharm has also entered into a distribution agreement (10 year) with Zydus Cadila, a prominent Indian global pharmaceutical company. Prior to this Dr Vikash Salig developed a consulting firm with specializations in business development in the pharmaceutical industry in Sub Saharan Africa, where he facilitated the start up of business operations in 19 countries in Africa. He was also Director, New Business Development for Aspen pharmacare Ltd ensuring growth of the group through acquisitions of products and intellectual property as well as developed new market segments locally and aboard.

Dominik Schnichels is the Head of the Pharma Task Force in DG Competition of the European Commission. The task force is in charge of the ongoing pharma sector inquiry. Before joing the Pharma Task Force he worked in various functions for the Commission, in particular on energy and trade matters. He is a lawyer by training who worked in an international law firm before entering in the Commission services.

Milan Todorovic joined Actavis from GlaxoSmithKline where he served as Country Manager for Serbia and Montenegro. Prior to GSK he was Country Manager Yugoslavia for the Whirlpool Corporation and held several Management positions at The Coca-Cola Company in the Balkan Region. Milan previously served as General Manager of Zdravlje Actavis in Serbia in 2004 and as Actavis Balkan’s Regional Director. Milan has completed an MBA degree from the Ashridge Business School in the UK and holds a degree in Industrial and Organisational Psychology from the University of Belgrade.

A Pharmacist, with 17 years experience in the Pharmaceutical Industry Field including management positions in all industry areas such as development, production, marketing and sales as well as some previous limited experience in academia. The current responsibility covers the set-up and leadership of a Global Marketing and Medical team in newly established BU Biopharmaceuticals in one of the Leading Generics companies – Sandoz. The responsibility includes setting-up and developing the leadership team in global headquarters as well as the net of teams in the countries.

Representative Henry A. Waxman represents California's 30th Congressional District. In 2007, Rep. Waxman became Chairman of the Committee on Oversight and Government Reform, the principal investigative Committee in the House. From 1997 to 2006, Rep. Waxman served as Ranking Member of the Government Reform Committee, conducting investigations into a wide range of topics from the high cost of prescription drugs to waste, fraud, and abuse in government contracting. He formed a Special Investigations Division that prepared hundreds of investigative reports on local and national topics for Members of Congress. From 1979 to 1994, Rep. Waxman chaired the Commerce Committee's Subcommittee on Health and the Environment. He served as the Subcommittee's Ranking Member in 1995 and 1996. Rep. Waxman continues to serve on the Committee on Energy and Commerce. Rep. Waxman has been involved in health issues since 1969, when he was appointed to the California State Assembly Health Committee. In Congress, Rep. Waxman has sponsored a long list of health bills that have been enacted into law. These measures include the Ryan White CARE Act, the Nutrition Labeling and Education Act, the Breast and Cervical Cancer Mortality Prevention Act, the Safe Medical Devices Act, the Patent Term Restoration and Drug Competition Act, and the Orphan Drug Act. Rep. Waxman has also passed legislation that improves the quality of nursing homes and home health services and that sets policy for childhood immunization programs, vaccine compensation, tobacco education programs, communicable disease research, community and migrant health centers, maternal and child health care, family planning centers, health maintenance organizations, and drug regulation and reform. Throughout the 1980s, Rep. Waxman championed national health care reform and improvements in the Medicare and Medicaid programs. He successfully led the fight for improved prenatal and infant care for low-income families, for protection against impoverishment for the spouses of persons in nursing homes, and for more services in the community for people needing long-term care. He has also been an advocate for prescription drug coverage in Medicare for people with high drug expenses. Prior to his election to Congress, Rep. Waxman served three terms in the California State Assembly, where he was chairman of the Health Committee, the Committee on Elections and Reapportionment, and the Select Committee on Medical Malpractice. He was the author of such major legislation as the Fair Campaign Practices Act, the Fair Credit for Women Law, and the legislation establishing standards for Health Maintenance Organizations in California. Rep. Waxman holds a bachelor's degree in political science from UCLA and a J.D. from the UCLA Law School.